397 related articles for article (PubMed ID: 9219316)
1. Meloxicam: selective COX-2 inhibition in clinical practice.
Furst DE
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
[TBL] [Abstract][Full Text] [Related]
3. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
Dequeker J; Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):946-51. PubMed ID: 9783758
[TBL] [Abstract][Full Text] [Related]
4. Review of clinical trials and benefit/risk ratio of meloxicam.
Barner A
Scand J Rheumatol Suppl; 1996; 102():29-37. PubMed ID: 8628979
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of aspirin-like drugs.
Vane JR; Botting RM
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):2-10. PubMed ID: 9219313
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
7. Safety of meloxicam: a global analysis of clinical trials.
Distel M; Mueller C; Bluhmki E; Fries J
Br J Rheumatol; 1996 Apr; 35 Suppl 1():68-77. PubMed ID: 8630641
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
Schoenfeld P
Am J Med; 1999 Dec; 107(6A):48S-54S. PubMed ID: 10628593
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
10. Meloxicam in rheumatoid arthritis.
Ahmed M; Khanna D; Furst DE
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):739-51. PubMed ID: 16863437
[TBL] [Abstract][Full Text] [Related]
11. [Selective cyclooxygenase-2 inhibitor].
Hettich M; Thomae K
Internist (Berl); 1997 Oct; 38(10):1007. PubMed ID: 9432492
[No Abstract] [Full Text] [Related]
12. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Goldenberg MM
Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
[TBL] [Abstract][Full Text] [Related]
14. Meloxicam.
Noble S; Balfour JA
Drugs; 1996 Mar; 51(3):424-30; discussion 431-32. PubMed ID: 8882380
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.
Yocum D; Fleischmann R; Dalgin P; Caldwell J; Hall D; Roszko P
Arch Intern Med; 2000 Oct; 160(19):2947-54. PubMed ID: 11041902
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
18. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
19. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam.
Tavakoli M
Pharmacoeconomics; 2003; 21(6):443-54. PubMed ID: 12678570
[TBL] [Abstract][Full Text] [Related]
20. Review article: COX-II inhibitors--a new generation of safer NSAIDs?
Donnelly MT; Hawkey CJ
Aliment Pharmacol Ther; 1997 Apr; 11(2):227-36. PubMed ID: 9146759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
